OBJECTIVE: The purpose of this study was to evaluate the role of different formulations and different administration kinetics of antenatal corticosteroid therapy on fetal heart rate. STUDY DESIGN: One hundred five patients who were at high risk for preterm delivery were assigned randomly to receive two injections of betamethasone acetate + phosphate, four injections of betamethasone phosphate, or four injections of dexamethasone phosphate. Computerized fetal heart rate was recorded daily through day 4. RESULTS: The three formulations did not differ in their effect on fetal heart rate, which varied significantly as a function of the time of injection. During treatment (day 0-day 1), fetal heart rate variability increased (+9%, P <.05), as did the number of fetal movements felt by the mother (+60% at day 0, P <.001). After treatment (day 2-day 3), variability fell significantly (-14%, P <.01), as did accelerations (-35% at day 2, P <.01). No modifications were still detectable on day 4. CONCLUSION: Antenatal corticotherapy is responsible for two different phases of fetal heart rate modifications that do not vary according to the corticosteroid or the dosage regimen.
RCT Entities:
OBJECTIVE: The purpose of this study was to evaluate the role of different formulations and different administration kinetics of antenatal corticosteroid therapy on fetal heart rate. STUDY DESIGN: One hundred five patients who were at high risk for preterm delivery were assigned randomly to receive two injections of betamethasone acetate + phosphate, four injections of betamethasone phosphate, or four injections of dexamethasone phosphate. Computerized fetal heart rate was recorded daily through day 4. RESULTS: The three formulations did not differ in their effect on fetal heart rate, which varied significantly as a function of the time of injection. During treatment (day 0-day 1), fetal heart rate variability increased (+9%, P <.05), as did the number of fetal movements felt by the mother (+60% at day 0, P <.001). After treatment (day 2-day 3), variability fell significantly (-14%, P <.01), as did accelerations (-35% at day 2, P <.01). No modifications were still detectable on day 4. CONCLUSION: Antenatal corticotherapy is responsible for two different phases of fetal heart rate modifications that do not vary according to the corticosteroid or the dosage regimen.
Authors: Mikael Norman; Aurelie Piedvache; Klaus Børch; Lene Drasbek Huusom; Anna-Karin Edstedt Bonamy; Elizabeth A Howell; Pierre-Henri Jarreau; Rolf F Maier; Ole Pryds; Liis Toome; Heili Varendi; Tom Weber; Emilija Wilson; Arno Van Heijst; Marina Cuttini; Jan Mazela; Henrique Barros; Patrick Van Reempts; Elizabeth S Draper; Jennifer Zeitlin Journal: JAMA Pediatr Date: 2017-07-01 Impact factor: 16.193
Authors: Augusto F Schmidt; Matthew W Kemp; Paranthaman S Kannan; Boris W Kramer; John P Newnham; Suhas G Kallapur; Alan H Jobe Journal: Pediatr Res Date: 2016-11-18 Impact factor: 3.756
Authors: Patricia A Nixon; Lisa K Washburn; Thomas Michael O'Shea; Hossam A Shaltout; Gregory B Russell; Beverly M Snively; James C Rose Journal: Pediatr Res Date: 2016-09-15 Impact factor: 3.756
Authors: Caroline A Crowther; Jane E Harding; Philippa F Middleton; Chad C Andersen; Pat Ashwood; Jeffrey S Robinson Journal: BMC Pregnancy Childbirth Date: 2013-05-03 Impact factor: 3.007